VIRIDIAN THERAPEUTICS INC

Insider trading at Viridian Therapeutics shows CEO Jennifer Tousignant buying and selling shares— a bullish signal of confidence in the biotech’s growth and upcoming milestones.

Viridian’s chief medical officer buys shares below market, boosting confidence in its thyroid eye disease pipeline and signaling a potential undervaluation for investors.

Insider buying at Viridian signals bullish confidence after FDA approval of its TED therapy, boosting long‑term investor outlook.

Fairmount’s $17 buy of 1.18 M Viridian shares after the $117 M equity round signals strong confidence in the biotech’s TED pipeline and growth strategy.